دورية أكاديمية
Hairy cell leukemia - etiopathogenesis, diagnosis and modern therapeutic approach.
| العنوان: | Hairy cell leukemia - etiopathogenesis, diagnosis and modern therapeutic approach. |
|---|---|
| المؤلفون: | Maćkowiak K; Department of Laboratory Diagnostic, Dr Jan Biziel University Hospital No. 2, Bydgoszcz, Poland., Jankowiak M; Department of Laboratory Diagnostic, Dr Jan Biziel University Hospital No. 2, Bydgoszcz, Poland., Szewczyk-Golec K; Department of Medical Biology and Biochemistry, Faculty of Medicine, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland., Hołyńska-Iwan I; Department of Pathobiochemistry and Clinical Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland. |
| المصدر: | Biochemia medica [Biochem Med (Zagreb)] 2024 Jun 15; Vol. 34 (2), pp. 020502. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Croatian Society for Medical Biochemistry and Laboratory Medicine Country of Publication: Croatia NLM ID: 9610305 Publication Model: Print Cited Medium: Internet ISSN: 1846-7482 (Electronic) Linking ISSN: 13300962 NLM ISO Abbreviation: Biochem Med (Zagreb) Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2012- : Zagreb : Croatian Society for Medical Biochemistry and Laboratory Medicine Original Publication: Zagreb : Hrvatsko društvo medicinskih biokemičara |
| مواضيع طبية MeSH: | Leukemia, Hairy Cell*/diagnosis , Leukemia, Hairy Cell*/therapy, Humans ; Male ; Diagnosis, Differential ; Mutation ; Proto-Oncogene Mas ; Proto-Oncogene Proteins B-raf/genetics ; Sex Factors |
| مستخلص: | Hairy cell leukemia (HCL) represents 2% of all leukemia cases, with men aged above 55 years being the most affected. The most common symptoms of this type of leukemia include splenomegaly, monocytopenia, and neutropenia. In the basic blood count examination, leukopenia with monocytopenia and granulocytopenia, as well as aplastic anemia and/or thrombocytopenia occur. The mutation of β-rapidly accelerated fibrosarcoma ( BRAF ) proto-oncogene, which can be found in nearly 100% of patients, is an important feature of HCL. Immunophenotypic analysis of the HCL cells reveals high expression of B-lineage antigens, including CD19, CD20, and CD22. Additionally, CD11c, CD25, CD103, and CD123 belong to specific markers of HCL. Lactate dehydrogenase activity and β-2-microglobulin concentration are also important in the patient's assessment. The differential diagnosis between HCL, hairy cell leukemia variant (HCL-V) and splenic marginal zone lymphoma (SMZL) is of first importance. Currently, the main treatment for HCL involves the use of purine analogues, excluding pregnant women, individuals with severe infections, and those with relapsing HCL. Competing Interests: Potential conflict of interest None declared. (Copyright Croatian Society of Medical Biochemistry and Laboratory Medicine.) |
| References: | Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):e616-e621. (PMID: 32418838) Rom J Morphol Embryol. 2013;54(3):575-9. (PMID: 24068406) Onco Targets Ther. 2021 Mar 09;14:1797-1805. (PMID: 33727830) Br J Haematol. 2020 Dec;191(5):730-737. (PMID: 33053222) Blood Rev. 2022 Jan;51:100888. (PMID: 34535326) J Clin Med. 2022 Dec 27;12(1):. (PMID: 36614994) Front Immunol. 2023 May 22;14:1207443. (PMID: 37283771) Curr Oncol Rep. 2023 Aug;25(8):833-840. (PMID: 37097545) F1000Res. 2018 Apr 27;7:. (PMID: 29770206) Am J Hematol. 2019 Dec;94(12):1413-1422. (PMID: 31591741) Front Biosci (Landmark Ed). 2015 Jun 01;20(7):1068-78. (PMID: 25961545) Blood. 2017 Feb 2;129(5):553-560. (PMID: 27903528) Mod Pathol. 2018 Nov;31(11):1717-1732. (PMID: 29955146) Am J Clin Pathol. 2011 Sep;136(3):390-9. (PMID: 21846914) Cancers (Basel). 2022 Feb 18;14(4):. (PMID: 35205796) Crit Rev Microbiol. 2020 May;46(3):270-287. (PMID: 32412856) Curr Opin Oncol. 2021 Sep 1;33(5):412-419. (PMID: 34264896) Am J Hematol. 2017 Dec;92(12):1398-1399. (PMID: 27727469) Blood Rev. 2014 Sep;28(5):197-203. (PMID: 25110197) Int J Mol Sci. 2021 Jul 21;22(15):. (PMID: 34360545) Am J Hematol. 2022 Feb 1;97(2):226-236. (PMID: 34710243) Vet Microbiol. 2010 Jan 27;140(3-4):297-309. (PMID: 19875249) Leuk Lymphoma. 2011 Jun;52 Suppl 2:94-8. (PMID: 21438839) Cancers (Basel). 2022 Feb 15;14(4):. (PMID: 35205704) Ann Oncol. 2015 Sep;26 Suppl 5:v100-7. (PMID: 26269205) Leuk Res. 2013 Apr;37(4):401-409. (PMID: 23347903) Eur J Haematol. 2020 Dec;105(6):682-691. (PMID: 32757401) Blood. 2022 Dec 22;140(25):2649-2650. (PMID: 36548021) Front Oncol. 2022 Dec 22;12:1068981. (PMID: 36620555) Genes (Basel). 2020 Nov 12;11(11):. (PMID: 33198372) Blood. 2014 Jan 9;123(2):177-83. (PMID: 24192579) Yonsei Med J. 2019 Oct;60(10):890-897. (PMID: 31538423) Biomolecules. 2020 Aug 03;10(8):. (PMID: 32756468) Blood. 2016 Oct 13;128(15):1918-1927. (PMID: 27554081) Ann Hematol. 2021 Mar;100(3):615-625. (PMID: 33216198) Rev Bras Hematol Hemoter. 2015 Mar-Apr;37(2):132-5. (PMID: 25818826) Chembiochem. 2018 Sep 17;19(18):1988-1997. (PMID: 29992710) Leuk Res. 1980;4(6):547-59. (PMID: 7206776) Best Pract Res Clin Haematol. 2015 Dec;28(4):208-16. (PMID: 26614899) |
| فهرسة مساهمة: | Keywords: BRAF V600E; cancer; hairy cell leukemia; molecular hematology; purine analogues |
| المشرفين على المادة: | EC 2.7.11.1 (BRAF protein, human) 0 (MAS1 protein, human) 0 (Proto-Oncogene Mas) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) |
| تواريخ الأحداث: | Date Created: 20240617 Date Completed: 20240617 Latest Revision: 20240621 |
| رمز التحديث: | 20240622 |
| مُعرف محوري في PubMed: | PMC11177658 |
| DOI: | 10.11613/BM.2024.020502 |
| PMID: | 38882583 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1846-7482 |
|---|---|
| DOI: | 10.11613/BM.2024.020502 |